Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


AHPA on ayurvedics

This article was originally published in The Tan Sheet

Executive Summary

The American Herbal Products Association recommends that Ayurvedic dietary supplement makers refrain from including "any ingredient that is processed with metals if the resultant presence of heavy metal(s) would cause the product containing the ingredient(s) to be adulterated under labeled or ordinary conditions of use," the group announces. The trade recommendation was adopted by AHPA's Board of Trustees during a July 15 meeting and amends the group's Code of Ethics, which AHPA members adhere to under the association's "obligations of membership." AHPA's board also amended an existing trade recommendation to advise that supplement labels should not suggest that use of the product will mask or defraud drug testing. The recommendation previously applied only to goldenseal supplements, but has been amended to apply to all dietary supplements. The recommendations become effective Dec. 15...

You may also be interested in...

Keeping Track: Submissions Galore Start The New Year; US FDA Clears New Indications For Enhertu, Xalkori

The latest drug development news and highlights from the Pink Sheet US FDA Performance Tracker

Vaccination Health Next Stop For Dentovations’ Self+ Immunity Supplement Line

Vacci Prep is first “supplement to establish a standard of care for consumers when preparing their immune system for vaccinations,” Dentovations says.

Balancing Innovation And Safety – The US and Australian Medtech Regulatory Systems Compared

Effective medical device regulation supports both safety and innovation needs. This article assesses how well the US FDA and the Australian TGA achieve this balance.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts